Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

63.81 +0.67 (+1.07%)
Streaming Delayed Price Updated: 1:15 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,799,540
Open 63.53
Bid (Size) 63.79 (5)
Ask (Size) 63.84 (6)
Prev. Close 63.14
Today's Range 62.50 - 67.73
52wk Range 9.340 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Viking Therepautics a Buy Now?
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales. 
Via The Motley Fool
Why Viking Therapeutics Stock Plummeted After Soaring Today
Are we ready for the Great Obesity Drug Gold Rush of the 2020s? 
Via The Motley Fool

Performance

YTD
+249.10%
+249.10%
1 Month
+1.28%
+1.28%
3 Month
+22.72%
+22.72%
6 Month
-18.41%
-18.41%
1 Year
+513.02%
+513.02%

More News

Read More
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
Via Investor's Business Daily
MarketBeat Week in Review – 10/28 - 11/1
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Unpacking the Latest Options Trading Trends in Viking Therapeutics
Via Benzinga
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
3 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Via MarketBeat
This High-Flying Stock Just Became a Better Buy
Via The Motley Fool
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Via The Motley Fool
S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump
Via Talk Markets
Topics Stocks
Exposures US Equities
An Overview of Viking Therapeutics's Earnings
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
Via Investor's Business Daily
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
Via The Motley Fool
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Via Investor's Business Daily
Exposures Product Safety
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia)
Via The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Via Benzinga
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.